<DOC>
	<DOCNO>NCT01725490</DOCNO>
	<brief_summary>Familial adenomatous polyposis ( FAP ) lead adenomas eventual adenocarcinoma colon less frequently , duodenum . Chemopreventive strategy study FAP patient delay development adenoma cancer . The non-steroidal anti-inflammatory drug ( NSAIDs ) selective cyclooxygenase-2 inhibitor show regression colorectal duodenal adenoma FAP patient . However , drug show gastrointestinal damage cardiovascular risk , new preventive strategy need . Metformin , biguanide , widely use treat diabetes mellitus , recently suggest suppressive effect tumorigenesis via mTOR-inhibiting pathway , significant safety issue long term use . The investigator devise double-blind randomized control trial evaluate effect metformin polyp colorectum duodenum non-diabetic FAP patient .</brief_summary>
	<brief_title>The Chemopreventive Effect Metformin Patients With Familial Adenomatous Polyposis : Double Blinded Randomized Controlled Study</brief_title>
	<detailed_description />
	<mesh_term>Adenomatous Polyposis Coli</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Patients familial adenomatous polyposis ( FAP ) 20 65 year age . 2 . FAP patient colonic duodenal polyp 3 . FAP patient five polyp 2mm diameter endoscopic examination . 1 . FAP patient history colectomy within previous 12 month need undergo colectomy within 8 month randomization . 2 . FAP patient malignant disease , include colorectal cancer . 3 . FAP patient used NSAIDs ( nonsteroidal antiinflammatory drug ) aspirin three time week within 6 month randomization . 4 . FAP patient diabetes mellitus . 5 . Pregnant breastfeeding patient . 6 . Patients abnormal result serum laboratory test ( renal function liver function test ) significant infectious respiratory disease .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>chemoprevention , metformin , familial adenomatous polyposis</keyword>
</DOC>